Search Results - "Heinonen, E. H."

Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects by HAASIO, K, NISSINEN, E, SOPANEN, L, HEINONEN, E. H

“…The toxicity profiles of entacapone and tolcapone, novel catechol- O-methyl-transferase (COMT) inhibitors, have been reported to differ from each other. It has…”
Get full text

Effect of selegiline on mortality in patients with Parkinson's disease : A meta-analysis by OLANOW, C. W, MYLLYLÄ, V. V, RINNE, U. K, SOTANIEMI, K. A, LARSEN, J.-P, PALHAGEN, S, PRZUNTEK, H, HEINONEN, E. H, KILKKU, O, LAMMINTAUSTA, R, MÄKI-IKOLA, O

“…The Parkinson's Disease Research Group of the United Kingdom (PDRG-UK) reported increased mortality in PD patients treated with levodopa plus selegiline…”
Get full text

Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat by HAASIO, K, SOPANEN, L, VAALAVIRTA, L, LINDEN, I.-B, HEINONEN, E. H

“…Entacapone and tolcapone are novel COMT (catechol-O-methyltransferase) inhibitors indicated for the adjunctive treatment of Parkinson's disease (PD) in…”
Get full text

Safety of selegiline (deprenyl) in the treatment of Parkinson's disease by HEINONEN, E. H, MYLLYLÄ, V

“…Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson's disease. As the…”
Get full text

Selegiline in the treatment of narcolepsy by HUBLIN, C, PARTINEN, M, HEINONEN, E. H, PUUKKA, P, SALMI, T

“…We treated 17 narcolepsy patients in a placebo-controlled, double-blind, crossover trial with 10-, 20-, 30-, and 40-mg daily doses of selegiline, a monoamine…”
Get full text

Selegiline as initial treatment in de novo parkinsonian patients by MYLLYLÄ, V. V, SOTANIEMI, K. A, VUORINEN, J. A, HEINONEN, E. H

“…To investigate the efficacy and safety of selegiline in the early phase of Parkinson's disease (PD), we carried out a placebo-controlled, double-blind,…”
Get full text

Selegiline delays the onset of disability in de novo parkinsonian patients by PALHAGEN, S, HEINONEN, E. H, HÄGGLUND, J, KAUGESAAR, T, KONTANTS, H, MÄKI-IKOLA, O, PALM, R, TURUNEN, J

Get full text

Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease by ALAFUZOFF, I, HELISALMI, S, HEINONEN, E. H, REINIKAINEN, K, HALLIKAINEN, M, SOININEN, H, KOIVISTO, K

“…A beneficial effect of selegiline (L-deprenyl) in Alzheimer's disease (AD) has been reported in several clinical studies. The brain tissue from 17 deceased…”
Get full text

Selegiline as the primary treatment of Parkinson's disease - a long-term double-blind study by Myllylä, V. V., Sotaniemi, K. A., Hakulinen, P., Mäki-lkola, O., Heinonen, E. H.

“…Introduction – To assess the therapeutic efficacy of selegiline combined with levodopa in the long‐term treatment of Parkinson's disease (PD). Material and…”
Get full text

Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites by Heinonen, E H, Anttila, M I, Lammintausta, R A

“…l-Deprenyl (selegiline), an irreversible and selective inhibitor of monoamine oxidase type B (MAO-B), is rapidly absorbed from the gastrointestinal tract and…”
Get more information

A review of the pharmacology of selegiline by Heinonen, E H, Lammintausta, R

“…Selegiline (1-deprenyl) is an irreversible inhibitor of monoamine oxidase (MAO) type B. Because in the human brain, dopamine is metabolised mainly by MAO-B,…”
Get more information

Role of selegiline in combination therapy of Parkinson's disease by Myllylä, V V, Sotaniemi, K, Mäki-Ikola, O, Rinne, U K, Heinonen, E H

Get full text

Selegiline in de novo parkinsonian patients: the Finnish study by Myllylä, V V, Sotaniemi, K A, Vuorinen, J A, Heinonen, E H

“…Selegiline (L-deprenyl) has been recommended as an antiparkinsonian drug to be used as an adjunct to therapy with L-dopa, if and when L-dopa starts to lose its…”
Get more information

Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease by Myllylä, V V, Heinonen, E H, Vuorinen, J A, Kilkku, O I, Sotaniemi, K A

“…In an earlier report of our placebo-controlled selegiline trial on de novo parkinsonian patients, we have shown that the need to start additional levodopa…”
Get more information

Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of Monoamine Oxidase Type B in Humans by Heinonen, Esa H., Anttila, Markku I., Karnani, Hari L., Nyman, Leena M., Vuorinen, Jouni A., Pyykkö, Kaija A., Lammintausta, Risto A. S.

“…Selegiline, an irreversible and selective inhibitor of monoamine oxidase type B (MAO‐B), is metabolized into desmethylselegiline, levomethamphetamine, and…”
Get full text

Comparative bioavailability of carbamazepine from two slow-release preparations by Reunanen, M, Heinonen, E H, Nyman, L, Anttila, M

“…In order to compare the multiple-dose bioavailability of carbamazepine (CBZ) from 2 slow-release preparations, Neurotol slow and Tegretol Retard, a…”
Get more information

Inhibition of Platelet Monoamine Oxidase Type B by Selegiline by Heinonen, Esa H., Anttila, Markku I., Nyman, Leena M., Pyykkö, Kaija A., Vuorinen, Jouni A., Lammintausta, Risto A. S.

“…Selegiline is an irreversible inhibitor of monoamine oxidase type B (MAO‐B). No comparative data are available on the MAO‐B inhibition caused by orally and…”
Get full text

Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease by HEINONEN, E. H, SAVAJÄRVI, M, KOTILA, M, HAJBA, A, SCHEININ, M

“…A double-blind, cross-over trial with 12 patients with Alzheimer's disease (AD) was carried out primarily to test the suitability of this design in the…”
Get full text

Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion by Mytilineou, C, Leonardi, E K, Radcliffe, P, Heinonen, E H, Han, S K, Werner, P, Cohen, G, Olanow, C W

“…Oxidative stress is thought to play an important role in the pathogenesis of Parkinson's disease (PD). Glutathione (GSH), a major cellular antioxidant, is…”
Get more information

Selegiline as a primary treatment of Parkinson's disease by Myllylä, V V, Sotaniemi, K A, Vuorinen, J A, Heinonen, E H

“…In order to investigate the efficacy of selegiline as a primary treatment in Parkinson's disease (PD), we carried out a placebo controlled, double-blind…”
Get more information